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Background: The aim of this trial was to investigate neurological outcome after emergency RT in MSCC of NSCLC
patients with acute neurological deficit.
Methods: This pilot trial was prospective, non-randomized, and monocentre, ten patients were treated from July
2012 until June 2013. After onset of neurological symptoms RT was started within 12 hours. The neurological outcome
was assessed at baseline, and six weeks after RT using the ASIA Impairment Scale (AIS).
Results: The results showed an improved neurological outcome in one patient (10%), one patient (10%) had a
decreased, and five patients (50%) a constant outcome after six weeks. Three patients (30%) died within the first six
weeks following RT, additional 4 patients (40%) died within 4 month due to tumor progression.
Conclusion: In this group of NSCLC patients we were able to show that emergency RT in MSCC with acute neurological
deficit had no considerable benefit in neurological outcome. Therefore, short-course regime or best supportive care due
to poor survival should be considered for these patients with additional distant metastases. Patients with favorable
prognosis may be candidates for long-course RT.
Trial Registration: Clinical trial identifier NCT 02000518.
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Malignant spinal cord compression (MSCC) is second-
ary to bone metastases to the vertebral column associ-
ated with mechanical compression of the myelon [1].
MSCC occurs in around 5% of terminal cancer patients
within the last 2 years of life [2], lung cancer accounts
for 15-20% of cases [3]. MSCC is a frequent medical
emergency, and the most common treatment offered is
radiotherapy. Treatment goals include maintenance of
neurological function, control of local tumor growth,
spine stabilization, and pain control [4]. Acute neuro-
logical deficit in MSCC is an emergency condition in
radiation oncology. Without treatment, the spinal cord
can be irreversibly damaged resulting in deteriorating or* Correspondence: harald.rief@med.uni-heidelberg.de
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stated.permanent sensorimotor deficits. Radiotherapy (RT) was
shown to be fast, time sparing, and a very effective treat-
ment option for MSCC [5]. Despite some reports about
the high efficacy of radiation treatment for oncological
emergencies, a standard of care is not well defined, espe-
cially the time interval of immediate RT after deficit, and
neurological outcome with respect to poor survival. The
objective of our trial was to investigate neurological out-
come after emergency RT in MSCC of non-small cell
lung cancer (NSCLC) patients with acute neurological
deficit.Methods
Subjects and recruitment
From July 2012 until June 2013, 15 consecutive patients
with histologically confirmed non-small cell lung cancer
and bone metastases of the thoracic or lumbar segments
of the vertebral column were screened for this trial in the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Patient characteristics at baseline
n %
Age (years)
Mean (SD) 58 (11)
Gender
Male 9 90
Female 1 10
KPS (median, range) 55 (50–70)
Histology Adenocarcinoma 9 90
Squamous cell carcinoma 1 10
Localization metastases
Thoracic 7 70
Lumbar 3 30
Number metastases
Mean (range) 2 (1–5)
Solitary 3 30
Multiple 7 70
Type of metastases
Mixed 1 10
Osteolytic 9 90
Distant metastases at baseline
Visceral 5 50
Brain 3 30
Lung 4 40
Ambulatory status prior to RT
Not ambulatory 9 90
Ambulatory before RT 1 10
Immunotherapy 2 20
Chemotherapy 7 70
Pathological fracture at baseline 0 0
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Clinic. The patients were subjected to a staging of their
vertebral column within the context of the computer tom-
ography scans (CT) and magnetic resonance imaging
(MRI) designed to plan the RT schedule prior to enrolment
into the trial. Inclusion criteria were an age of 18 to 80
years, acute neurological symptom caused by MSCC, no
RT in this spinal area before, and written consent to par-
ticipate. Out of 15 patients considered eligible 5 patients
were excluded due to neurological deficit confirmed longer
than 12 hours. The remaining 10 patients fulfilled the in-
clusion and were enrolled into the trial (Figure 1). The
study was approved by the Heidelberg Ethics Committee
(Nr. S-514/2011).
Design and procedures
This is a prospective, controlled, explorative trial to in-
vestigate the neurological outcome after emergency RT
in MSCC of NSCLC patients with acute neurological
deficit. RT started within 12 hours after onset of neuro-
logical symptoms. The target parameters were measured
at the start of radiotherapy (t0), and six weeks after
RT (t1). The target parameters comprise the documenta-
tion and completion of the ASIA Impairment Scale (AIS),
and the recording of patient-specific data. The data of
the patient records were collected by the authors. Patient
characteristics are shown in Table 1.
The primary endpoint was neurological outcome,
assessed using the ASIA Impairment Scale (AIS), which is
specially designed to standard neurological classification
for patients with spinal cord injury [6]. In sensory level,
the light touch and pin prick (right and left) was tested in
each dermatomes (0 = absent, 1 = impaired, 2 = normal).
The total of light touch and pin prick was 112 pts. left and
right each. In motor level, the upper limb and lower limb10 patients enrolled
5 excluded neurological 
15 patients screened
7 completed ASIA score 
6 weeks follow-up
3 died due to 
tumor progression
Figure 1 Flow of participants through the trial.
Radiotherapy schedule (Gy)
Single dose (median, range) 3 (2.5-3)
Cumulative dose (median, range) 30 (30–35)
SD Standard deviation, RT Radiotherapy.total was 50 pts. left and right each. The muscle grading
was defined 0 = total paralysis, 1 = palpable or visible con-
traction, 2 = active movement, full range of motion, gravity
eliminated, 3 = active movement, full range of motion,
against gravity, 4 = active movement, full range of motion,
against gravity and provides some resistance, 5 = active
movement, full range of motion, against gravity and pro-
vides normal resistance. The survival was defined as begin
RT (begin neurological symptom) to death.
Radiotherapy was performed in the Radiooncology
Department of the Heidelberg University Clinic. After
virtual simulation was performed to plan the radiation
schedule, radiotherapy was carried out over a dorsal
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specific vertebral body affected as well as the ones immedi-
ately above and below. 8 patients (80%) were treated with
10 × 3 Gy, 2 patients (20%) with 14 x 2.5 Gy. The median
individual dose in all patients was 3 Gy (range 2.5-3 Gy),
the median total dose 30 Gy (range 30–35 Gy). The indi-
vidual and total doses were decided separately for each
individual patient.
All variables were analyzed descriptively by tabulation
of the measures of the empirical distributions. According
to the scale level of the variables, means, standard devia-
tions, medians as well as minimum and maximum or
absolute and relative frequencies, respectively, will be
reported.
Results
The median follow-up was 2.1 months. During the trial
there were no adverse events and no dropouts. The median
Karnofsky performance score (KPS) was 55, only one
(10%) patient had a pre-radiotherapy ambulatory status.
According the ASIA score, one patient (10%) im-
proved the neurological outcome, one patient (10%)
had a decreased, and five patients (50%) a constant out-
come after six weeks. The motor and sensory score
were considerably similar after six weeks, and summa-
rized in Tables 2 and 3.Table 2 Five categories of the ASIA impairment scale
A Complete. No sensory or motor function
is preserved in the sacral segments S4-S5.
B Sensory Incomplete. Sensory but not
motor function is preserved below the
neurological level and includes the sacral
segments S4-S5 (light touch, pin prick at S4-S5:
or deep anal pressure (DAP)), and no motor
function is preserved more than three levels below
the motor level on either side of the body.
C Motor Incomplete. Motor function is
preserved below the neurological level, and
more than half of key muscle functions below the
single neurological level of injury (NLI) have a
muscle grade less than 3 (Grades 0–2).
D Motor Incomplete. Motor function is
preserved below the neurological level, and at
least half (half or more) of key muscle functions
below the NLI have a muscle grade > 3.
E Normal. If sensation and motor function
are graded as normal in all segments, and the
patient had prior deficits, then the AIS grade is E.Three patients (30%) died within the first six weeks
following RT, additional 4 patients (40%) died within 4
month due to tumor progression. The median survival
time was 2.57 month (SD = 0.53) from begin RT to death
(Figure 2). We found three groups with different survival
after RT. The three cases with rapid deaths were com-
pared to brain and/or visceral metastases. The group of
patients (n = 4) who died within 4 months was compared
to progression of primary site, one (10%) decreased in
neurological outcome. In all cases, the number or spinal
localization of metastases did not correlate with survival.
In 3 patients, survival was longer than 4 month, all of them
had no other distant metastases, and one improved the
neurological outcome. The chemotherapy or immunother-
apy before RT showed no influence in survival.
Discussion
Acute neurological deficit in MSCC is an emergency
condition in radiation oncology. A rapidly developed
neurological symptom in MSCC is a rare condition,
most of symptoms develop slowly. RT and surgery are
the most frequently applied treatment modalities [1]. RT
is the most commonly used option due to poor prognosis
in lung cancer [7]. Time factor of begin RT (emergency
RT within 12 hours) after neurological symptom cause of
MSCC is not well defined. Our results showed no consid-
erable benefit in neurological outcome after emergency
RT in MSCC of NSCLC patients with acute neurological
deficit. Only one patient (10%) improved to outcome after
6 weeks. Christian et al. showed in 1033 patients, that
emergency RT produces only 50% improvement rate [5],
however this was a result of different primary tumour
sites. Another work of Rades et al. in 84 patients presented
an improvement of motor function occurred in 24% after
radiotherapy [8]. The emergency RT in MSCC of NSCLC
patients with acute neurological deficit is very rare, there-
fore our sample size was low. Nevertheless this prospect-
ive trial presented first results of neurological outcome
according the ASIA score after emergency RT. Previous
trials showed no detriment to functional outcome and
response rate in different radiotherapy schedules [9-11].
The schedules in our trial were decided separately for each
individual patient. The survival of patients with MSCC
depends on the primary tumour, lung cancer is generally
dismal [1]. The life expectancy of most MSCC patients is
quite short, with reported median survival of only few
months [12]. In our trial, 7 patients (70%) died within 4
months after RT. These patients may be candidates for
short-course RT, single fraction RT, or even best support-
ive care alone. In the retrospective study of Rades et al.
1852 patients with different tumours the factors predicting
for improved survival were female gender, a favourable
histology, the absence of visceral or other extensive bone
metastases, a good performance status, being ambulatory
Table 3 Results of ASIA score at baseline and after 6 weeks
Motor Baseline 6 weeks
Mean SD Min Max Mean SD Min Max
Upper limb 48 4.3 38 50 47 7.9 29 50
Lower limb 25 18.3 10 50 30 18.4 14 50
Voluntary anal contraction n = 4 (40%) n = 4 (40%)
Sensory Baseline 6 weeks
Mean SD Min Max Mean SD Min Max
Light touch 82 21.8 50 108 76 23.2 53 108
Pin prick 74 24.9 42 107 73 29.1 51 106
AIS A B C D E A B C D E
3 0 4 3 0 2 0 2 3 0
AIS ASIA Impairment Scale.
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radiotherapy [1]. All these predicting factors were in our
short-survival group absent. We were not able to show pre-
dicting factors due the small sample size. In this unfavour-
able group of patients, the optimal dose would be just a
single 8 Gy dose, as it has been shown to provide equivalent
functional recovery, local control and survival compared
with longer schedules [13]. In three cases (30%) of our par-
ticipants, survival was longer than 4 months. These
patients had no other distant metastases, and one im-
proved the neurological outcome, and may be candidates
for long-course RT such as 10 × 3 Gy or 14 × 2.5 Gy for
better local control. Validated scoring systems are needed
to identify long-term survivors for decision of fractionation
[14,15]. Estimating the prognosis is critical to achieving aFigure 2 Kaplan-Meier curve for survival (begin neurological symptombalance between effective therapy and the burden of treat-
ment. Treatment can be individualized by reviewing simple
prognosis scales. For patients with a poor prognosis, a
single fraction of 8 Gy or 5 × 4 Gy is just as effective as
multiple fractions and much more convenient [16].
Most institutions give corticosteroids in addition to ra-
diation treatment, which is strongly recommended in
the literature [17]. In the present study, all patients were
treated with corticosteroids 24 mg per day.
Limitations of our trial were the single arm design and
low number of participants. The strength of our work
comprised the first performance of emergency RT within
12 hours after neurological symptom and prospective
assessment of neurological outcome according to a vali-
dated score.to death).
Rief et al. Radiation Oncology 2013, 8:297 Page 5 of 5
http://www.ro-journal.com/content/8/1/297Conclusion
In this group of NSCLC patients we were able to show
that emergency RT in MSCC with acute neurological
deficit had no considerable benefit in neurological out-
come. Short-course regimens or best supportive care
due to poor survival should be considered for these
patients with additional distant metastases. Patients
with favorable prognosis may be candidates for long-
course RT.
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